Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Other neoplasm 1 Other hematologic neoplasm 1 Lymphoid 1 Gynecologic 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Interventions

fludarabine 5 Educational Status 5 fludarabine phosphate 4 Whole-Body Irradiation 4 Mycophenolic Acid 4 Methods 4 Melphalan 4 Magnetic Resonance Spectroscopy 4 Early Intervention, Educational 4 Cyclophosphamide 4 Busulfan 4 Biopsy 4 Taxes 3 Tacrolimus 3 Specimen Handling 3 Peripheral Blood Stem Cell Transplantation 3 Paclitaxel 3 Interviews as Topic 3 venetoclax 2 Sirolimus 2 Patient Reported Outcome Measures 2 Nivolumab 2 Mesna 2 Health Promotion 2 Colposcopy 2 Cisplatin 2 Aminolevulinic Acid 2 Albumin-Bound Paclitaxel 2 toripalimab 1 tirbanibulin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Psilocybin × Other neoplasm × 1 year × Clear all

NCT04950608 2026-02-17

PATH

Dana-Farber Cancer Institute

Phase 2 Completed

15 enrolled 26 charts

Hospice

Data powered by HemOnc (CC BY 4.0) Colophon ⚡